Synopsis
Synopsis
0
VMF
Annual Reports
NA
0
Data Compilation #PharmaFlow
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
1. A-hyrocort
2. Cortisol Hemisuccinate
3. Cortisol Succinate
4. Cortisol Succinate, Sodium Salt
5. Cortisol-21-(hydrogen Succinate)
6. Hydrocortisone 21-sodium Succinate
7. Hydrocortisone Hemisuccinate
8. Hydrocortisone Hemisuccinate Anhydrous
9. Hydrocortisone Succinate
10. Pregn-4-ene-3,20-dione, 21-(3-carboxy-1-oxopropoxy)-11,17-dihydroxy-, (11beta)-
11. Solu-cortef
12. Sopolcort H
13. Sopolkort
1. 125-04-2
2. A-hydrocort
3. Hydrocortisone 21-hemisuccinate Sodium Salt
4. Cortop
5. Solu-cortef
6. Arcocort
7. Buccalsone
8. Corlan
9. Emi-corlin
10. Cortisol 21-(sodium Succinate)
11. Flebocortid
12. Hycorace
13. Intracort
14. Nordicort
15. Oralsone
16. Solu-hizon
17. Solu-glyc
18. Hydrocortisone 21-sodium Succinate
19. Ef-cortelan Soluble
20. 50lqb69s1z
21. Chebi:5782
22. Cortisol Sodium Succinate
23. Hydrocortisone Hemisuccinate
24. Cortisol Sodium Hemisuccinate
25. Sodium Hydrocortisone Succinate
26. Cortisol Hemisuccinate Sodium Salt
27. Hydrocortisone Sodium Hemisuccinate
28. Hydrocortisone 21-sodium Succinide
29. Sodium Hydrocortisone 21-succinate
30. Nsc-9152
31. Hydrocortisone 21-hemisuccinate Sodium
32. Hydrocortisone Sodium 21-hemisuccinate
33. Sodium Hydrocortisone 21-hemisuccinate
34. Hydrocortisone Hemisuccinate Sodium Salt
35. Dsstox_cid_28932
36. Dsstox_rid_83198
37. Dsstox_gsid_49006
38. Hydrocortisone 21-succinate Sodium Salt
39. Sodium 17-hydroxycorticosterone 21-succinate
40. Hidrokortizon
41. U 4905
42. Nositrol
43. Rapicort
44. Lycortin-s
45. Cas-125-04-2
46. Sodium;4-[2-[(8s,9s,10r,11s,13s,14s,17r)-11,17-dihydroxy-10,13-dimethyl-3-oxo-2,6,7,8,9,11,12,14,15,16-decahydro-1h-cyclopenta[a]phenanthren-17-yl]-2-oxoethoxy]-4-oxobutanoate
47. Flebocortid [inj.]
48. Hydro-adreson Aquosum
49. Ncgc00022248-03
50. Idrocortisone B. I. L.
51. Unii-50lqb69s1z
52. Hydrocortisone Succinate,sodium Salt
53. Einecs 204-725-5
54. A-hydrocort (tn)
55. Solu-cortef (tn)
56. Hydrocortisone 21-(sodium Succinate)
57. Mfcd00069472
58. Hydrocortisone-21-hemisuccinate Sodium
59. Hydrocortisone-21-hemisuccinate Sodium Salt
60. Cortisol 21-hemisuccinate Sodium Salt
61. Hydrocortisone Sodium Succinate [usp:ban:jan]
62. Schembl93508
63. Hydrocortisoni Natrii Succinas
64. Mls000069545
65. Chembl1200495
66. Dtxsid2049006
67. Cortisol 21-hemisuccinate Sodium
68. Hms2234h22
69. Succinic Acid Hydrocortisone Sodium
70. Tox21_113501
71. Akos024386298
72. Tox21_113501_1
73. Cortisol, Succinate, Sodium Salt
74. Ncgc00022248-04
75. Pregn-4-ene-3,20-dione, 21-(3-carboxy-1-oxopropoxy)-11,17-dihydroxy-, Monosodium Salt, (11.beta.)-
76. Smr000058768
77. Eu-0100623
78. Hydrocortisone Sodium Succinate (jp17/usp)
79. Hydrocortisone Sodium Succinate [jan]
80. U4905
81. C08178
82. D00978
83. F20569
84. H 2270
85. Hydrocortisone Sodium Succinate [mart.]
86. Hydrocortisone Sodium Succinate [vandf]
87. Hydrocortisone 21-sodium Succinate [mi]
88. Hydrocortisone Sodium Succinate [who-dd]
89. Hydrocortisone Sodium Succinate [who-ip]
90. Cortisol, 21-(hydrogen Succinate), Monosodium Salt
91. Hydrocortisone Sodium Succinate [orange Book]
92. Hydrocortisone Sodium Succinate [usp Monograph]
93. Hydrocortisoni Natrii Succinas [who-ip Latin]
94. Q27106890
95. Hydrocortisone 21-hemisuccinate Sodium Salt, >=90% (hplc)
96. Hydrocortisone 21-hemisuccinate Sodium Salt, Powder, Bioreagent, Suitable For Cell Culture
97. (11beta)-21-(3-carboxy-1-oxopropoxy)-11,17-dihydroxypregn-14-ene-3,20-dione, Monosodium Salt
98. Pregn-4-ene-3,20-dione, 21-(3-carboxy-1-oxopropoxy)-11,17-dihydroxy-, Monosodium Salt, (11beta)-
Molecular Weight | 484.5 g/mol |
---|---|
Molecular Formula | C25H33NaO8 |
Hydrogen Bond Donor Count | 2 |
Hydrogen Bond Acceptor Count | 8 |
Rotatable Bond Count | 7 |
Exact Mass | 484.20731229 g/mol |
Monoisotopic Mass | 484.20731229 g/mol |
Topological Polar Surface Area | 141 Ų |
Heavy Atom Count | 34 |
Formal Charge | 0 |
Complexity | 915 |
Isotope Atom Count | 0 |
Defined Atom Stereocenter Count | 7 |
Undefined Atom Stereocenter Count | 0 |
Defined Bond Stereocenter Count | 0 |
Undefined Bond Stereocenter Count | 0 |
Covalently Bonded Unit Count | 2 |
1 of 4 | |
---|---|
Drug Name | A-hydrocort |
PubMed Health | Hydrocortisone (Injection) |
Drug Classes | Endocrine-Metabolic Agent, Immune Suppressant |
Active Ingredient | Hydrocortisone sodium succinate |
Dosage Form | Injectable |
Route | Injection |
Strength | eq 100mg base/vial |
Market Status | Prescription |
Company | Hospira |
2 of 4 | |
---|---|
Drug Name | Solu-cortef |
PubMed Health | Hydrocortisone |
Drug Classes | Anti-Inflammatory, Corticosteroid, Intermediate, Corticosteroid, Weak, Endocrine-Metabolic Agent, Gastrointestinal Agent, Hemorrhoidal Anti-Inflammatory, Hydrocortisone, Immune Suppressant |
Drug Label | SOLU-CORTEF Sterile Powder is an anti-inflammatory glucocorticoid that contains hydrocortisone sodium succinate as the active ingredient. SOLU-CORTEF Sterile Powder is available in several packages for intravenous or intramuscular administration.100... |
Active Ingredient | Hydrocortisone sodium succinate |
Dosage Form | Injectable |
Route | Injection |
Strength | eq 500mg base/vial; eq 250mg base/vial; eq 1gm base/vial; eq 100mg base/vial |
Market Status | Prescription |
Company | Pharmacia And Upjohn |
3 of 4 | |
---|---|
Drug Name | A-hydrocort |
PubMed Health | Hydrocortisone (Injection) |
Drug Classes | Endocrine-Metabolic Agent, Immune Suppressant |
Active Ingredient | Hydrocortisone sodium succinate |
Dosage Form | Injectable |
Route | Injection |
Strength | eq 100mg base/vial |
Market Status | Prescription |
Company | Hospira |
4 of 4 | |
---|---|
Drug Name | Solu-cortef |
PubMed Health | Hydrocortisone |
Drug Classes | Anti-Inflammatory, Corticosteroid, Intermediate, Corticosteroid, Weak, Endocrine-Metabolic Agent, Gastrointestinal Agent, Hemorrhoidal Anti-Inflammatory, Hydrocortisone, Immune Suppressant |
Drug Label | SOLU-CORTEF Sterile Powder is an anti-inflammatory glucocorticoid that contains hydrocortisone sodium succinate as the active ingredient. SOLU-CORTEF Sterile Powder is available in several packages for intravenous or intramuscular administration.100... |
Active Ingredient | Hydrocortisone sodium succinate |
Dosage Form | Injectable |
Route | Injection |
Strength | eq 500mg base/vial; eq 250mg base/vial; eq 1gm base/vial; eq 100mg base/vial |
Market Status | Prescription |
Company | Pharmacia And Upjohn |
Anti-Inflammatory Agents
Substances that reduce or suppress INFLAMMATION. (See all compounds classified as Anti-Inflammatory Agents.)
API/FDF Prices: Book a Demo to explore the features and consider upgrading later
API Imports and Exports
Importing Country | Total Quantity (KGS) |
Average Price (USD/KGS) |
Number of Transactions |
---|
Upgrade, download data, analyse, strategize, subscribe with us
DRUG PRODUCT COMPOSITIONS
Related Excipient Companies
Excipients by Applications
Global Sales Information
Market Place
Patents & EXCLUSIVITIES
REF. STANDARDS & IMPURITIES
ABOUT THIS PAGE
53
PharmaCompass offers a list of Hydrocortisone Sodium Succinate API manufacturers, exporters & distributors, which can be sorted by GMP, USDMF, JDMF, KDMF, CEP (COS), WC, Price,and more, enabling you to easily find the right Hydrocortisone Sodium Succinate manufacturer or Hydrocortisone Sodium Succinate supplier for your needs.
Send us enquiries for free, and we will assist you in establishing a direct connection with your preferred Hydrocortisone Sodium Succinate manufacturer or Hydrocortisone Sodium Succinate supplier.
PharmaCompass also assists you with knowing the Hydrocortisone Sodium Succinate API Price utilized in the formulation of products. Hydrocortisone Sodium Succinate API Price is not always fixed or binding as the Hydrocortisone Sodium Succinate Price is obtained through a variety of data sources. The Hydrocortisone Sodium Succinate Price can also vary due to multiple factors, including market conditions, regulatory modifications, or negotiated pricing deals.
A Nositrol manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Nositrol, including repackagers and relabelers. The FDA regulates Nositrol manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Nositrol API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
click here to find a list of Nositrol manufacturers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PhamaCompass.
A Nositrol supplier is an individual or a company that provides Nositrol active pharmaceutical ingredient (API) or Nositrol finished formulations upon request. The Nositrol suppliers may include Nositrol API manufacturers, exporters, distributors and traders.
click here to find a list of Nositrol suppliers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PharmaCompass.
A Nositrol DMF (Drug Master File) is a document detailing the whole manufacturing process of Nositrol active pharmaceutical ingredient (API) in detail. Different forms of Nositrol DMFs exist exist since differing nations have different regulations, such as Nositrol USDMF, ASMF (EDMF), JDMF, CDMF, etc.
A Nositrol DMF submitted to regulatory agencies in the US is known as a USDMF. Nositrol USDMF includes data on Nositrol's chemical properties, information on the facilities and procedures used, and details about packaging and storage. The Nositrol USDMF is kept confidential to protect the manufacturer’s intellectual property.
click here to find a list of Nositrol suppliers with USDMF on PharmaCompass.
The Pharmaceuticals and Medical Devices Agency (PMDA) established the Japan Drug Master File (JDMF), also known as the Master File (MF), to permit Japanese and foreign manufacturers of drug substances, intermediates, excipients, raw materials, and packaging materials (‘Products’) to voluntarily register confidential information about the production and management of their products in Japan.
The Nositrol Drug Master File in Japan (Nositrol JDMF) empowers Nositrol API manufacturers to present comprehensive information (e.g., production methods, data, etc.) to the review authority, i.e., PMDA (Pharmaceuticals & Medical Devices Agency).
PMDA reviews the Nositrol JDMF during the approval evaluation for pharmaceutical products. At the time of Nositrol JDMF registration, PMDA checks if the format is accurate, if the necessary items have been included (application), and if data has been attached.
click here to find a list of Nositrol suppliers with JDMF on PharmaCompass.
In Korea, the Ministry of Food and Drug Safety (MFDS) is in charge of regulating pharmaceutical products and services.
Pharmaceutical companies submit a Nositrol Drug Master File in Korea (Nositrol KDMF) to the MFDS, which includes comprehensive information about the production, processing, facilities, materials, packaging, and testing of Nositrol. The MFDS reviews the Nositrol KDMF as part of the drug registration process and uses the information provided in the Nositrol KDMF to evaluate the safety and efficacy of the drug.
After submitting a Nositrol KDMF to the MFDS, the registered manufacturer can provide importers or distributors with the registration number without revealing confidential information to Korean business partners. Applicants seeking to register their Nositrol API can apply through the Korea Drug Master File (KDMF).
click here to find a list of Nositrol suppliers with KDMF on PharmaCompass.
A Nositrol CEP of the European Pharmacopoeia monograph is often referred to as a Nositrol Certificate of Suitability (COS). The purpose of a Nositrol CEP is to show that the European Pharmacopoeia monograph adequately controls the purity of Nositrol EP produced by a given manufacturer. Suppliers of raw materials can prove the suitability of Nositrol to their clients by showing that a Nositrol CEP has been issued for it. The manufacturer submits a Nositrol CEP (COS) as part of the market authorization procedure, and it takes on the role of a Nositrol CEP holder for the record. Additionally, the data presented in the Nositrol CEP (COS) is managed confidentially and offers a centralized system acknowledged by numerous nations, exactly like the Nositrol DMF.
A Nositrol CEP (COS) is recognised by all 36 nations that make up the European Pharmacopoeia Convention. Nositrol CEPs may be accepted in nations that are not members of the Ph. Eur. at the discretion of the authorities there.
click here to find a list of Nositrol suppliers with CEP (COS) on PharmaCompass.
A Nositrol written confirmation (Nositrol WC) is an official document issued by a regulatory agency to a Nositrol manufacturer, verifying that the manufacturing facility of a Nositrol active pharmaceutical ingredient (API) adheres to the Good Manufacturing Practices (GMP) regulations of the importing country. When exporting Nositrol APIs or Nositrol finished pharmaceutical products to another nation, regulatory agencies frequently require a Nositrol WC (written confirmation) as part of the regulatory process.
click here to find a list of Nositrol suppliers with Written Confirmation (WC) on PharmaCompass.
National Drug Code is a comprehensive database maintained by the FDA that contains information on all drugs marketed in the US. This directory includes information about finished drug products, unfinished drug products, and compounded drug products, including those containing Nositrol as an active pharmaceutical ingredient (API).
The FDA updates the NDC directory daily. The NDC numbers for Nositrol API and other APIs are published in this directory by the FDA.
The NDC unfinished drugs database includes product listing information submitted for all unfinished drugs, such as active pharmaceutical ingredients (APIs), drugs intended for further processing and bulk drug substances for compounding.
Pharmaceutical companies that manufacture Nositrol as an active pharmaceutical ingredient (API) must furnish the FDA with an updated record of all drugs that they produce, prepare, propagate, compound, or process for commercial distribution in the US at their facilities.
The NDC directory also contains data on finished compounded human drug products that contain Nositrol and are produced by outsourcing facilities. While these outsourcing facilities are not mandated to assign a Nositrol NDC to their finished compounded human drug products, they may choose to do so.
click here to find a list of Nositrol suppliers with NDC on PharmaCompass.
Nositrol Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of Nositrol GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Nositrol GMP manufacturer or Nositrol GMP API supplier for your needs.
A Nositrol CoA (Certificate of Analysis) is a formal document that attests to Nositrol's compliance with Nositrol specifications and serves as a tool for batch-level quality control.
Nositrol CoA mostly includes findings from lab analyses of a specific batch. For each Nositrol CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
Nositrol may be tested according to a variety of international standards, such as European Pharmacopoeia (Nositrol EP), Nositrol JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Nositrol USP).